Close Menu

NEW YORK (GenomeWeb) — Adaptive Biotechnologies intends to offer 12.5 million shares of its common stock at between $15 and $17 apiece in its planned initial public offering, the immunosequencing firm said in a filing with the US Securities and Exchange Commission on Monday.

If the shares float at the top end of the expected range, Adaptive will raise $212.5 million through the IPO. If the underwriters of the IPO exercise their option to buy an additional 1.875 million shares, Adaptive could raise up to $244.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.